Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 16:01 ET
|
Xenon Pharmaceuticals Inc.
Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful “end-of-Phase 2” interactions with FDA in MDD; Phase...
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
May 08, 2024 16:01 ET
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will...
Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024 16:01 ET
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will...
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
May 02, 2024 16:01 ET
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced it will report its first...
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
April 16, 2024 08:30 ET
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced two oral presentations...
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 10, 2024 08:30 ET
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 04, 2024 16:01 ET
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
March 12, 2024 16:01 ET
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
March 05, 2024 16:01 ET
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 29, 2024 16:01 ET
|
Xenon Pharmaceuticals Inc.
XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures; completion of patient enrollment in...